|18th February 2021||Dan Puckett||3,080||Payment by withholding||$123.19||$379,425.20|
|18th February 2021||Isaac Zacharias||3,719||Payment by withholding||$123.19||$458,143.61|
|17th February 2021||James E Flynn||32,884||Open or private purchase||$19.00||$624,796.00|
|17th February 2021||James E Flynn||133,558||Open or private purchase||$19.00||$2,537,602.00|
|9th February 2021||James E Flynn||1,717,033||Conversion of derivative||$0.00|
|9th February 2021||James E Flynn||665,000||Open or private purchase||$17.00||$11,305,000.00|
|8th February 2021||Laura Francis||9,839||Open or private sale||$33.10||$325,718.13|
|8th February 2021||Laura Francis||9,839||Exercise of derivative||$4.32||$42,504.48|
|5th February 2021||Laura Francis||803||Exercise of derivative||$4.32||$3,468.96|
|5th February 2021||Laura Francis||803||Open or private sale||$33.10||$26,579.30|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 6/10.
Shockwave Medical, Inc. operates as a medical device company. It focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease.